Wells Fargo & Company Boosts Liquidia (NASDAQ:LQDA) Price Target to $25.00

Liquidia (NASDAQ:LQDA - Get Free Report) had its price objective raised by investment analysts at Wells Fargo & Company from $23.00 to $25.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Wells Fargo & Company's price objective suggests a potential upside of 73.01% from the stock's previous close.

Several other equities analysts have also recently weighed in on LQDA. Wall Street Zen raised shares of Liquidia from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. BTIG Research reiterated a "buy" rating on shares of Liquidia in a research note on Tuesday, May 27th. Oppenheimer set a $13.00 price objective on shares of Liquidia and gave the company an "underperform" rating in a research report on Monday, May 19th. Scotiabank upped their target price on shares of Liquidia from $36.00 to $37.00 and gave the company a "sector outperform" rating in a report on Wednesday, May 28th. Finally, HC Wainwright raised their target price on shares of Liquidia from $29.00 to $35.00 and gave the company a "buy" rating in a research note on Wednesday, May 28th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $26.89.

Liquidia Trading Up 2.3%

Shares of Liquidia stock traded up $0.32 during trading hours on Thursday, reaching $14.45. 3,075,557 shares of the company's stock were exchanged, compared to its average volume of 1,200,626. The stock has a market cap of $1.24 billion, a P/E ratio of -8.87 and a beta of 0.04. The company has a 50 day moving average of $15.12 and a two-hundred day moving average of $14.11. Liquidia has a fifty-two week low of $8.26 and a fifty-two week high of $19.41.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The company had revenue of $3.12 million for the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. As a group, analysts expect that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Rajeev Saggar sold 2,450 shares of the stock in a transaction on Monday, April 21st. The stock was sold at an average price of $13.67, for a total transaction of $33,491.50. Following the sale, the insider now directly owns 263,152 shares of the company's stock, valued at approximately $3,597,287.84. This represents a 0.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jason Adair sold 1,856 shares of the business's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the transaction, the insider now owns 184,304 shares of the company's stock, valued at $2,501,005.28. The trade was a 1.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 33,138 shares of company stock valued at $450,233. 26.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Liquidia

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in Liquidia by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company's stock worth $41,834,000 after acquiring an additional 115,367 shares in the last quarter. LM Advisors LLC acquired a new stake in Liquidia in the fourth quarter valued at $25,948,000. Whitefort Capital Management LP increased its stake in shares of Liquidia by 16.8% in the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company's stock valued at $23,370,000 after buying an additional 285,220 shares during the period. Vestal Point Capital LP boosted its stake in shares of Liquidia by 17.3% in the 4th quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company's stock valued at $20,698,000 after purchasing an additional 260,000 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Liquidia by 8.2% in the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock worth $15,753,000 after acquiring an additional 101,597 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).